Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Trial Profile

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms CHRONOS; LIBERTY AD CHRONOS
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 28 Sep 2019 Results (n=250) of sub-analysis of three studies (AD-1021; LIBERTY AD SOLO 1 and LIBERTY AD CHRONOS) assessing efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis, published in the British Journal of Dermatology.
    • 13 Aug 2019 Results assessing the safety of Dupilumab by clinical findings in patients undergoing treatment for moderate-to-severe Atopic Dertmatitis using pooled data (n=2116) from 3 clinical trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2 and LIBERTY AD CHRONOS), published in the British Journal of Dermatology.
    • 05 Aug 2019 According to a Regeneron Pharmaceuticals media release, the European Commission has approved Dupixent (dupilumab) in the European Union (EU) to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. The decision is based on data from the LIBERTY AD program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top